Marijuana use is on the rise, including older adults. Data presented at 2023 AHA (cardiology) meeting suggests that marijuana user have higher risk of MI & CVA; & daily marijuana users were 34% more likely to develop heart failure (in hospitalized adults) https://t.co/EnEnf6pqdr https://t.co/GXSv30AFLr

NEJM: Clinical Examination of the Cervical Spine (full read, with video). Great overview of Cx exam, useful in evaluation of axial neck pain, radiculopathy, or myelopathy; info on dermatomes, reflexes, Lhermites sign, etc https://t.co/EMizgh6Dtg https://t.co/6tdx1LBSDh

New download available, titled "Dealing with Infections" https://t.co/hsOuJoFokg https://t.co/G3MZ9BQo0X

Oral Surveillance Study Alters Practice at VA Safety risks found in a postmarketing trial with the JAKi tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for RA patients in the VA health system, researchers found. https://t.co/6WktHCkrI1 https://t.co/8wpAeLsBbw

H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV). https://t.co/QEPQJkfSjE https://t.co/pFk2mF22ex

Optimal Management of DQT The treatment of DQT was examined by systematic review in JAMA, suggesting that local corticosteroid injection + a thumb spica immobilization was associated w/significant pain-relieving and functional benefits. https://t.co/Qo5XGwCRsy https://t.co/58n74oFbfh

Study of TNFi tapering in 108 axSpA patients in remission. Gradual tapering over 2 yrs resulted in flares in 99% (108). - 27% flared at 2/3 dose - 20% at 1/2 dose - 27% at 1/3 dose - 25% w/ discontinuation WHY WOULD YOU DO THIS? I DONT! https://t.co/g8L7E4lcqG https://t.co/oaBILUrlmd

BMJ State of the Art (full read) review of ADVANCES in LUPUS THERAPY (Morand EF, et al). - Recent SLE RCTs - Pathogenesis, genetics, epigenetics - Phenotypes - Emerging treatments - Guidelines on Rx https://t.co/qZFvQkaFeO https://t.co/r9IriOR8FF

FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/4f6Ew5KGmg https://t.co/SldJ6MXMw7 https://t.co/KfCww7doef

Analysis of German RABBIT registry did not show more MACE events in pts w/ JAK inhibitors compared to other DMARDs. 154 MACE w/ 14203 Rx episodes (21218 Pt-Yrs). IRs were 0.68 JAKi, 0.62 TNFi, 0.76 bdMARDs and 0.95 csDMARDs; higher in CV risk pts https://t.co/luUK9M9IM9 https://t.co/z8lxjWscCR

Metanalysis of 26 studies (2252) pts w/ HBsAg-/HBcAb+ RA treated with b/tsDMARDs, shows the pooled HBV reactivation rate was 2.0% HBV reactivation higher w/ RTX (9%), ABA (6%), JAKi (1%); none w/ IL-6i or TNF-i More reactivation if pt is HBsAb- (OR=4.56) https://t.co/V60nkUSpjj https://t.co/jnZKnY0Zuk

FDA Approves Infliximab Biosimilar for Subcutaneous Use Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease. https://t.co/oTGm16k6Uo https://t.co/tSysmriP7q https://t.co/TIZc8rxwxM